Month: May 2024

CHARLOTTE, N.C., May 15, 2024 (GLOBE NEWSWIRE) — Cheetah Net Supply Chain Service Inc. (“Cheetah Net” or the “Company”) (NASDAQ: CTNT), a supplier of parallel-import vehicles sourced in the U.S. to be sold in the PRC market and a logistics and warehouse service provider, today announced the closing of its follow-on offering of 13,210,000 shares of Class A common stock. Each share of Class A common stock was sold at an offering price of $0.62, for gross proceeds of $8.19 million, before deducting placement agent fees and other offering fees and expenses. All the shares of Class A common stock were offered by the Company. Cheetah Net intends to use the net proceeds received from the offering to fund working capital and to develop its warehousing and logistics services. AC Sunshine Securities LLC acted as the sole placement agent...

Beverly Hills, California., May 15, 2024 (GLOBE NEWSWIRE) — Nordicus Partners Corporation (OTCQB: NORD) (“Nordicus” or the “Company”), a financial consulting company specializing in providing Nordic and U.S. Life Sciences companies with optimal conditions to establish themselves on the U.S. market, announced today that it has entered into an agreement with Orocidin A/S (“Orocidin”) to acquire a 95% stake from eleven of Orocidin’s shareholders for $38,000,000. Nordicus will be issuing 38 million restricted common shares in an all-stock transaction to the selling shareholders. With Nordicus becoming Orocidin’s single largest shareholder, Henrik Rouf, CEO of Nordicus, and Henrik Keller, Director of Nordicus, will both join Orocidin’s Board of Directors. Henrik Rouf stated, “We are thrilled to become the largest shareholder of Orocidin,...

DUBLIN, Ireland, May 15, 2024 (GLOBE NEWSWIRE) — Fusion Fuel Green PLC (Nasdaq: HTOO) (“Fusion Fuel” or the “Company”), an emerging leader in the green hydrogen sector, today announced that on May 8, 2024, the Company received a deficiency notice (the “Notice”) from the Listing Qualifications Department of the Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that, since the Company’s Form 20-F for the fiscal year ended December 31, 2023 reported shareholders’ equity of $3,022,125, the Company no longer complied with Nasdaq listing rules (the “Rules”) requiring companies listed on the Nasdaq Global Market to maintain a minimum of $10,000,000 in shareholders’ equity. Under the Rules, the Company has 45 calendar days from the date of the Notice to submit a plan (the “Plan”) to regain compliance. If the Plan is accepted, Nasdaq...

PRESS RELEASE        Paris, 15 May 2024 – 17 h 45 YOUR OPERATIONAL LEASING SOLUTION FOR SUSTAINABLE TRANSPORTATION Stable activity in 1st quarter 2024€36.4 million in revenues for the first three months of the year, stable compared with 1st quarter 2023 (-2%) Leasing revenue on owned equipment up +13.1%Total restated revenue for the 1st quarter 2024 amounts to €36.4 million (€36.6 million at constant currency and scope1), stable compared to €37.1 million of restated revenue at the same period in 2023.Restated Revenue from activities (*) Q1 2024   Q1 2023   Variation  (in € thousand)Leasing revenue on owned equipment 19,381 17,139 2,242Ancillary services 3,021 5,031 -2,010Total leasing activity 22,402 22,170 232Sales of owned equipment 12,213 13,053 -840Total sales of equipment 12,213 13,053 -840Total...

PHAXIAM provides Business and Financial Update for the First Quarter of 2024 Webinar (in French) today, May 15, 2024, at 6.00 pm CESTAccelerated clinical efforts to roll-out PHAXIAM’s strategy in order to create a global phage-therapy leader in high-value indications Cash and cash equivalents of €5.8 million, as of March 31, 2024Lyon (France) and Cambridge (MA, US), May 15, 2024, at 5.45 pm CEST – PHAXIAM Therapeutics (Euronext: PHXM; FR0011471135), a biopharmaceutical company developing innovative treatments for severe and resistant bacterial infections, today provides a business and financial update for the first quarter of 2024. Thibaut du Fayet, Chief Executive Officer of PHAXIAM Therapeutics, stated: “Almost a year after the creation of PHAXIAM, the company is well on track to become a leading player in phage therapies targeting...

Strasbourg, France, May 15, 2024, 05:45 p.m. CEST – The Combined Ordinary and Extraordinary General Meeting of Transgene’s shareholders was held today (May 15, 2024) at 10:00 a.m. at the Company’s headquarters (400 boulevard Gonthier d’Andernach – Parc d’Innovation – 67400 Illkirch-Graffenstaden, France). The meeting was chaired by Alessandro Riva, Chairman and CEO, to approve the Company’s financial statements for the year ended December 31, 2023, and to vote on the other resolutions submitted for approval. The replay of the Combined General Meeting is available via Transgene’s website and here.   The Combined General Meeting adopted all resolutions recommended by the Board of Directors. The Combined General Meeting notably has appointed one new director, Michel Baguenault de Puchesse, as non-independent director. Michel Baguenault de...

Disclosure of the total number of voting rights and shares, provided pursuant to article L. 233-8 II of the French Commercial Code and the Article 223-16 of the Règlement général de l’Autorité des marchés financiers  (Regulation of the French stock market authority) Company name of the issuer:         Renault SA 122 – 122 bis Avenue du Général Leclerc 92100 Boulogne-Billancourt (ISIN code FR0000131906 – RNO)Date   Total number of issued shares     Total number of voting rightsApril 30, 2024     295,722,284     Theoretical number of voting rights(1) : 400,614,117  Exercisable number of voting rights(2) : 431,271,785(1)   Pursuant to Article 223-11 of the Règlement général de l’Autorité des marchés financiers, number calculated on the basis of all shares to which voting rights are attached, including shares for which...

Translation for information purposes only Monthly information relating to the total number of voting rights and outstanding shares In accordance with articles L. 233-8-II of the French Commercial Code and 223-16 of the Autorité des Marchés Financiers General Regulation Reporting company:Corporate name: McPhy Energy Public Limited company (société anonyme) with Board of Directors Registered office: 79 rue Général Mangin, 38100 Grenoble Registered under number 502 205 917 R.C.S. Grenoble Euronext Paris Compartment C (ISIN code: FR0011742329 – MCPHY)Date Total number of outstanding shares Total number of voting rights*Gross Net30.04.2024 29,031,788 30,979,220 29,752,696* Total number of voting rights (i) “gross” calculated on the basis of all the shares to which voting rights are attached, including those...

CASINO, GUICHARD-PERRACHONA French société anonyme (joint-stock company) with share capital of €375,740,444.29Registered office: 1, Cours Antoine Guichard42000 Saint-Etienne, FranceRegistered with the Saint-Etienne Trade and Companies Registry Availability of information relatedto the Ordinary and Extraordinary Annual General Meetingof 11 June 2024 CASINO, GUICHARD-PERRACHON’s shareholders are invited to participate in the Ordinary and Extraordinary Shareholders’ Meeting which will be held on first call, on Tuesday 11 June 2024 at 10 am (CET) at Maison de la Mutualité – 24, rue Saint-Victor – 75005 Paris, France. The preliminary notice of meeting published in the Bulletin des Annonces Légales Obligatoires (BALO) on 3 May 2024 which contains the agenda, draft resolutions and describes the arrangements for participating and voting...